microRNAs and response to statins in patients with hypercholesterolemia: from basic research to precision medicine [0.03%]
微小核糖核酸与高胆固醇血症患者他汀类药物的治疗反应：从基础研究到精准医疗
Tomás Zambrano,Luis A Salazar
Tomás Zambrano
Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy? [0.03%]
任重而道远：从预测和预防氟尿嘧啶毒性到提高疗效？
Seid Hamzic,Ursula Amstutz,Carlo R Largiadèr
Seid Hamzic
Marc-André Legault,Jean-Claude Tardif,Marie-Pierre Dubé
Marc-André Legault
Blood lipids are important modifiable risk factors for coronary heart disease and various drugs have been developed to target lipid fractions. Considerable efforts have been made to identify genetic variants that modulate responses to drugs...
Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy [0.03%]
用于抗血小板治疗患者的CYP2C19基因分型的可行性及其应用
Thomas O Bergmeijer,Gerrit Ja Vos,Daniël Mf Claassens et al.
Thomas O Bergmeijer et al.
Aim: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment t...
SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients [0.03%]
SLC04A1、SLC22A2和SLC28A2基因变异与类风湿关节炎患者甲氨蝶呤的疗效和毒性无关
Frank Eektimmerman,Jesse J Swen,Stefan Böhringer et al.
Frank Eektimmerman et al.
Aim: A third of rheumatoid arthritis patients discontinue methotrexate treatment due to inefficacy or toxic side effects. Recently, an association between SLC04A1 rs2236553, SLC22A2 rs624249 and rs316019, and SLC28A2 rs10...
"What do we know about tacrolimus pharmacogenetics in transplant recipients?" [0.03%]
“移植受者的他克莫司药物基因组学我们了解多少？"]
Dirk Rj Kuypers
Dirk Rj Kuypers
Elise M A Slob,Susanne J H Vijverberg,Mariëlle W Pijnenburg et al.
Elise M A Slob et al.
A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure [0.03%]
血管紧张素受体基因型对中国心力衰竭患者坎地沙坦疗效影响的前瞻性研究
Simon de Denus,Marie-Pierre Dubé,René Fouodjio et al.
Simon de Denus et al.
Aim: To evaluate the impact of AGTR1 A1166C (rs5186) on the response to candesartan in patients with heart failure. Materials & methods: ...
Clinical Trial
Pharmacogenomics. 2018 May;19(7):599-612. DOI:10.2217/pgs-2018-0004 2018
Letícia C Tavares,Leiliane R Marcatto,Paulo C J L Santos
Letícia C Tavares
Warfarin pharmacogenomics has been an extensively studied field in the last decades as it is focused on personalized therapy to overcome the wide interpatient warfarin response variability and decrease the risk of side effects. In this expe...
Deep learning in pharmacogenomics: from gene regulation to patient stratification [0.03%]
深度学习在药物基因组学中的应用：从基因调控到患者分型
Alexandr A Kalinin,Gerald A Higgins,Narathip Reamaroon et al.
Alexandr A Kalinin et al.
This Perspective provides examples of current and future applications of deep learning in pharmacogenomics, including: identification of novel regulatory variants located in noncoding domains of the genome and their function as applied to p...